# ZD6474 Phase IIa Dose Finding Multicentre Study

> **NCT00252746** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 53 (actual)

## Conditions studied

- Non Small Cell Lung Carcinoma

## Interventions

- **DRUG:** ZD6474 (vandetanib) 100mg
- **DRUG:** ZD6474 (vandetanib) 200mg
- **DRUG:** ZD6474 (vandetanib) 300mg

## Key facts

- **NCT ID:** NCT00252746
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2016-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00252746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00252746, "ZD6474 Phase IIa Dose Finding Multicentre Study". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00252746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*